drugset / Trial / NCT05694130

Tacrolimus Plus Glucocorticoid for Severe Thrombocytopenia in SS

NCT05694130

Phase 2/3 Unknown 110 enrolled Peking Union Medical College Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This 12-week randomized, open-label study evaluates the efficacy and safety of Tacrolimus combined with Glucocorticoid for Sjogren's syndrome patients with severe thrombocytopenia.

Timeline

Start
2023-02
Primary completion
2024-09
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule 1 mg Oral
Subject Tacrolimus Small molecule 2 mg Oral
Background Prednisolone Other / unclassified 7.5 mg Oral

Indications